Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth

Expert Opinion on Investigational Drugs

Volumn 18, Issue 11, 2009, Pages 1595-1604

  Wang, Zheng ^a   Zhou, Jian ^a   Fan, Jia ^a   Qiu, Shuang Jian ^a   Yu, Yao ^a   Huang, Xiao Wu ^a   Sun, Jian ^a   Tan, Chang Jun ^a   Dai, Zhi ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl 2 family; Hepatocellular carcinoma; Oxaliplatin

Indexed keywords

OXALIPLATIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; MICROARRAY ANALYSIS; MOUSE; NICK END LABELING; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; FLOW CYTOMETRY; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, ELECTRON, TRANSMISSION; ORGANOPLATINUM COMPOUNDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73849130300     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903292626     Document Type: Article

References (28)

1. Sutcliffe R, Maguire D, Portmann B, et al. Selection of patients with hepatocellular carcinoma for liver transplantation. Br J Surg 2006;93:11-18
2. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005;23:8093-8108
3. Liau KH, Ruo L, Shia J, et al. Outcome of partial hepatectomy for large (>10 cm) hepatocellular carcinoma. Cancer 2005;104:1948-1955
4. Tang ZY. Hepatocellular carcinoma surgery-review of the past and prospects for the 21st century. J Surg Oncol 2005;91:95-96
5. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 1996;52:1855-1865
6. Marchetti P, Galla DA, Russo FP, et al. Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line. Anticancer Res 2004;24:219-226
7. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:1898-1903
8. Li Y, Tian B, Yang J, et al. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol 2004;130:460-468
9. Nanjundan M, Nakayama Y, Cheng KW, et al. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 2007;67:3074-3084
10. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-676
11. Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 2002;59:1914-1927
12. Ehrsson H, Wallin I, Yachnin J. Pharmacokinetics of oxaliplatin in humans. Med Oncol 2002;19:261-265
13. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-656
14. Cory S, Vaux DL, Strasser A, et al. Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res 1999;59:1685s-92s
15. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-164
16. Arango D, Wilson AJ, Shi Q, et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 2004;91:1931-1946
17. Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996;334:1561-1567 (Pubitemid 26177483)
18. Holmes WF, Soprano DR, Soprano KJ. Early events in the induction of apoptosis in ovarian carcinoma cells by CD437: activation of the p38 MAP kinase signal pathway. Oncogene 2003;22(41):6377-6386
19. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004;1644:229-249
20. Manion MK, Hockenbery DM. Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther 2003;2:105s-14s
21. Watanabe J, Kushihata F, Honda K, et al. Bcl-xL overexpression in human hepatocellular carcinoma. Int J Oncol 2002;21:515-519
22. Hayward RL, MacPherson JS, Cummings J, et al. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol Cancer Ther 2004;3:169-178
23. Bruix J, Hessheimer AJ, Forner A, et al. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 2006;25:3848-3856
24. Ezhevsky SA, Dowdy SF. Protein transduction strategies for target and mechanism validation. In: Prendergast G, editor, Molecular cancer therapeutics. New Jersey: John Wiley; 2004
25. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-885
26. Yen Y, Lim DW, Chung V, et al. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. Am J Clin Oncol 2008;31:317-322
27. Uhm JE, Park JO, Lee J, et al. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009;63:929-935
28. Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008;112:2733-2739